In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

•Baricitinib has been suggested as a promising therapy for COVID-19.•Baricitinib modulates in vitro SARS-CoV-2-specific-response in a whole blood platform.•Baricitinib decreases viral-specific-response mainly in mild/moderate COVID-19. Baricitinib seems a promising therapy for COVID-19. To fully-inv...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infection Vol. 82; no. 4; pp. 58 - 66
Main Authors:	Petrone, Linda, Petruccioli, Elisa, Alonzi, Tonino, Vanini, Valentina, Cuzzi, Gilda, Najafi Fard, Saeid, Castilletti, Concetta, Palmieri, Fabrizio, Gualano, Gina, Vittozzi, Pietro, Nicastri, Emanuele, Lepore, Luciana, Grifoni, Alba, Antinori, Andrea, Vergori, Alessandra, Ippolito, Giuseppe, Cantini, Fabrizio, Goletti, Delia
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.04.2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association
Subjects:	Azetidines Baricitinib COVID-19 COVID-19 Drug Treatment Cytokines Humans IGRA Purines Pyrazoles SARS-CoV-2 Specific immune-response Sulfonamides COVID-19 SARS-CoV-2 Specific immune-response Baricitinib IGRA
ISSN:	0163-4453, 1532-2742, 1532-2742
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!